We are excited to share that SwanBio is now part of Spur Therapeutics. Our potential first-in-class gene therapy candidate for adrenomyeloneuropathy (AMN) has joined Spur’s expanding pipeline of next-generation genetic medicines. Learn more at spurtherapeutics.com.
SwanBio Therapeutics
Biotechnology Research
Bala Cynwyd, Pennsylvania 6,339 followers
Researching & developing leading-edge gene therapies to deliver dramatic clinical efficacy for neurological diseases
About us
SwanBio is now part of Spur Therapeutics. Our potential first-in-class gene therapy candidate for adrenomyeloneuropathy (AMN) has joined Spur’s expanding pipeline of next-generation genetic medicines. Learn more at spurtherapeutics.com.
- Website
-
www.spurtherapeutics.com
External link for SwanBio Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Bala Cynwyd, Pennsylvania
- Type
- Privately Held
- Founded
- 2018
- Specialties
- Neurology and Gene Therapy
Locations
-
Primary
150 Monument Rd
Suite 207
Bala Cynwyd, Pennsylvania 19004, US
-
245 Main Street, 2nd Fl
Cambridge, Massachusetts 02142, US
Employees at SwanBio Therapeutics
Updates
-
Of the 6000+ known rare diseases, why was SwanBio founded to focus on AMN? Listen & learn as we strive to every day – and especially today, #RareDiseaseDay. We are indebted to the adrenomyeloneuropathy community for the trust and faith they have put in our team to develop the first clinical-stage gene therapy for this devastating disease. We constantly strive to better understand the impact of AMN on patients, caregivers, and families in order to make a meaningful difference. #RDD2024
-
Mental Health Matters! Health is shaped by many factors, including relationships and physical wellbeing. For those with rare diseases, community support is crucial. It provides understanding and a sense of belonging, essential for mental health. Physical health directly impacts mental wellness, emphasising the need for a holistic health approach, especially in rare diseases. This Rare Disease Day, let's spotlight the importance of mental health in our community. Sharing experiences and support, we strengthen our collective resilience. . . #RareDiseaseDay #ShareYourColours #Awareness #LightUpForRare
-
As Rare Disease Day approaches, it's important to remember: whether you're living with a rare disease or caring for someone who is, you're not alone. Around 300 million people worldwide, 5% of the global population, are on this journey with you. Together, we form a community marked by resilience and determination. 💪💙 Let's use this day to spread awareness and understanding. Share your story today: rarediseaseday.org! . . #RareDiseaseDay #ShareYourColours #Awareness #LightUpForRare
-
We’re getting ready to honor #RareDiseaseDay later this month with a conversation between our co-founders about WHY. Why does SwanBio exist? Why are we so committed to developing a gene therapy for #AMN? Why is drug development for rare diseases so different than more common conditions? Thank you Florian Eichler for joining us to remind us that 'rare' does not mean different, separate, or alone. #showyourstripes #adrenomyeloneuropathy #RDD24
-
This Thurs, Feb 15: Our Co-Founder and CSO Karen Kozarsky, Ph.D. will join other industry leaders to discuss #genetherapy manufacturing. Register below!
📣 Next week! Register for our can’t-miss webinar with leading gene therapy experts! Join us for an engaging webinar with Endpoints News, where industry leaders David Dismuke, Jenny Holt, Karen Kozarsky, Ph.D., and John Maslowski will examine the essential "7 questions gene therapy developers should ask their CDMO (and what they will ask you!)" We will explore crucial topics like yield, commercial readiness, validated scale-down models, automation of analytical assays, and more. Register here ➡️ https://bit.ly/3SMK31W
-
We kicked off February by gathering some of our Swans to celebrate our 6th birthday. Thank you to our extended Pond who has supported us along the way: our team members, research partners, clinicians, clinical trial sites, and members of the AMN community. We are incredibly proud of what we've learned about #adrenomyeloneuropathy and AAV #genetherapy over the past 6 years, with your collaboration and shared insights. Cheers to many more!
-
Our CSO Karen Kozarsky, Ph.D. is pleased to be joining other industry experts next month (Thurs, Feb 15) to discuss #genetherapy manufacturing. Register today!
Don’t miss our must-see webinar with Endpoints News featuring notable industry leaders to discuss “7 questions gene therapy developers should ask their CDMO (and what they will ask you!)" We’ll delve into the key questions around yield, commercial readiness, validated scale-down models, automation of analytical assays, and more. Speakers: David Dismuke Jenny Holt Karen Kozarsky, Ph.D. John Maslowski Register here ➡️ https://hubs.li/Q02gjHZp0
-
SwanBio Therapeutics reposted this
Don’t miss our must-see webinar with Endpoints News featuring notable industry leaders to discuss “7 questions gene therapy developers should ask their CDMO (and what they will ask you!)" We’ll delve into the key questions around yield, commercial readiness, validated scale-down models, automation of analytical assays, and more. Speakers: David Dismuke Jenny Holt Karen Kozarsky, Ph.D. John Maslowski Register here ➡️ https://hubs.li/Q02gjHZp0
-
While we welcome new leaders to the Pond this week, we are also taking the time to thank & recognize Thomas D. Anderson for his steadfast leadership. With Topher Brooke stepping in as our new COO, Tom will be moving from his position as CEO into a strategic advisor role, and maintaining his seat on our Board. Tom's poised and humble leadership have set the tone for our culture and core values over the past four years. His spirit of collaboration has led our team through multiple key accomplishments, including - most recently - the initiation of our higher-dose cohort in the study of our gene therapy for #AMN, following a recommendation from the DSMB. Thank you, Tom! And see you soon. #genetherapy #adrenomyeloneuropathy #CEOoftheyear